TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.

doi:10.1158/1078-0432.CCR-19-3034

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2020

Sinn Marianne, Sinn Bruno V, Treue Denise, Keilholz Ulrich, Damm Frederik, Schmuck Rosa, Lohneis Philipp, Klauschen Frederick, Striefler Jana K, Bahra Marcus, Bläker Hendrik, Bischoff Sven, Pelzer Uwe, Oettle Helmut, Riess Hanno, Budczies Jan, Denkert Carsten

Abstract excerpt

PURPOSE: We performed next-generation sequencing (NGS) in the CONKO-001 phase III trial to identify clinically relevant prognostic and predictive mutations and conducted a functional validation in The Cancer Genome Atlas (TCGA) sequencing data. EXPERIMENTAL DESIGN: Patients of the CONKO-001 trial received curatively intended surgery for pancreatic adenocarcinoma (PDAC) followed by adjuvant chemotherapy with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Clinical Trials, Phase III as Topic

Share to Deoxycytidine

Share to Gemcitabine

Share to Neoplasm Recurrence, Local

Share to Pancreatectomy

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed

Identifiers

PMID: 32234756
DOI: 10.1158/1078-0432.CCR-19-3034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.PMID 32234756Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic.Semantic proximity Read ↗

Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.Semantic proximity Read ↗

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.Semantic proximity Read ↗

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelSemantic proximity Read ↗

Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancerSemantic proximity Read ↗

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.Semantic proximity Read ↗

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.Semantic proximity Read ↗

Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.Semantic proximity Read ↗

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.